Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays

Tumor tissue mutational burden (TMB) has emerged as a promising predictive biomarker for immune checkpoint therapy. Measuring TMB from circulating tumor DNA (ctDNA) found in plasma is attractive in tissue-constrained indications. We compared the performance of two plasma-based commercial TMB assays...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Ping, Poehlein, Christian H., Marton, Matthew J., Laterza, Omar F., Levitan, Diane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331610/
https://www.ncbi.nlm.nih.gov/pubmed/30643180
http://dx.doi.org/10.1038/s41598-018-37128-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331610/
https://www.ncbi.nlm.nih.gov/pubmed/30643180
http://dx.doi.org/10.1038/s41598-018-37128-y

Ejemplares similares